ArticleInternational journal of biological sciences2026
HMGA2 Stabilizes hnRNPK to Drive YAP-Dependent Liver Metastasis in Pancreatic Cancer.
Article in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer (PC) is a highly aggressive malignant neoplasm with a propensity for liver metastasis (LM), which significantly contributes to poor patient prognosis, but its molecular mechanism remains incompletely elucidated. In this study, we demonstrated that high mobility group protein A2 (HMGA2) is markedly elevated in LM tissues and circulating tumor cells (CTCs) of PC patients. Mechanistically, HMGA2 binds to heterogeneous nuclear ribonucleoprotein K (hnRNPK) via "AT-hook" functional motif, suppressing its ubiquitination to block proteasomal degradation. This interaction promotes the transcriptional activation of Yes-associated protein (YAP) by facilitating hnRNPK binding to the YAP promoter and thereby enhancing metastatic potential of PC. Functional assays validate that hnRNPK mediates HMGA2's pro-metastatic function, and YAP acts as the indispensable downstream effector of this cascade. Our findings establish the HMGA2/hnRNPK-YAP axis as a critical regulator of LM and propose targeting this pathway as a promising therapeutic strategy for metastatic PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.